This grant from the National Institutes of Health (NIH) is for the purpose of accelerating the development of novel neurotherapeutic drugs using small molecule compounds. It offers investigators a unique opportunity to access a robust virtual pharma drug development network, typically unavailable to academia. Successful applicants will receive U01 funding to conduct biological testing of compound analogs in their own laboratories. Crucially, the grant also provides no-cost access to essential drug development services, including medicinal chemistry optimization, IND-directed pharmacology and toxicology, and Phase I clinical testing. This initiative targets researchers with disease assays and promising small molecule compounds for nervous system and psychiatric disorders that are not yet suitable for clinical trials, encouraging collaborative drug discovery.
Opportunity ID: 79293
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-NS-12-002 |
| Funding Opportunity Title: | NIH Blueprint for Neuroscience Research Grand Challenge: Developing Novel Drugs for Disorders of the Nervous System (U01) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Environment Health Income Security and Social Services |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.113 — Environmental Health |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 16, 2011 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Dec 15, 2011 |
| Current Closing Date for Applications: | Dec 15, 2011 |
| Archive Date: | Jan 15, 2012 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $125,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education State governments Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Private institutions of higher education Small businesses City or township governments For profit organizations other than small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Public housing authorities/Indian housing authorities |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Foreign (non-U.S.) components of U.S. Organizations are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The National Institutes of Health (NIH) announces a unique opportunity for investigators working with small molecule compounds to gain access to a robust virtual pharma drug development network to develop neurotherapeutic drugs. Successful applicants to this FOA will become collaborative participants in this network, receiving both funding and no-cost access to contracted drug development services that are not typically available to the academic research community. Funding will be provided through a U01 cooperative agreement mechanism to conduct biological testing of compound analogs in disease assays and models in the investigators laboratory. No-cost drug development services will also be provided, including medicinal chemistry optimization, IND-directed pharmacology and toxicology, and Phase I clinical testing. Researchers in possession of disease assays and small molecule compounds that show promise for treating nervous system and psychiatric disorders, but that are not yet suitable for clinical testing, are strongly encouraged to apply. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-12-002.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| ADOBE-FORMS-B1 | ADOBE-FORMS-B1 | PKG00040610 | May 10, 2011 | Dec 15, 2011 | View |
Package 1
Mandatory forms
79293 RR_SF424_1_2-1.2.pdf
79293 RR_OtherProjectInfo_1_3-1.3.pdf
79293 RR_KeyPersonExpanded_1_2-1.2.pdf
79293 PerformanceSite_1_4-1.4.pdf
79293 PHS398_ResearchPlan_1_3-1.3.pdf
79293 PHS398_CoverPageSupplement_1_4-1.4.pdf
79293 PHS398_Checklist_1_3-1.3.pdf
Optional forms
79293 RR_Budget-1.1.pdf
79293 RR_SubawardBudget-1.2.pdf
79293 PHS_CoverLetter_1_2-1.2.pdf
79293 PHS398_ModularBudget-1.1.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
